The seven stages of an idea  by de Cannière, Didier
T
D
Editorials de Cannière
5
ED
ITO
RIA
Lhe seven stages of an idea
idier de Cannière, MD, PhD
N
n
n
g
p
p
b
o
t
o
a
c
i se
i
o
s
s
c
p
w
p
l
c
c
e
t afe
bFrom the Departments of Cardiac Surgery,
Erasme Academic Hospital and Tivoli Uni-
versity Hospital, Brussels University, Brus-
sels, Belgium.
D. de Cannière reports consulting fees from
Intuitive Surgical and lecture fees from
Tyco Healthcare.
Received for publication Feb 28, 2007; re-
visions received March 22, 2007; accepted
for publication March 29, 2007.
Address for reprints: D. de Cannière, MD,
PhD, Professor and Chief, Departments of
Cardiac Surgery, Erasme Academic Hospi-
taland Tivoli University Hospital, Brussels
University, 1070 Brussels Belgium and
7100 La Louvière Belgium (E-mail: didier.
decanniere@ulb.ac.be).
J Thorac Cardiovasc Surg 2007;134:562-4
0022-5223/$32.00
Copyright © 2007 by The American Asso-
ciation for Thoracic Surgery
See related articles on pages
559 and 710.n
doi:10.1016/j.jtcvs.2007.03.035
62 The Journal of Thoracic and Cardioorman Shumway, recalling the pioneering days of heart transplantation,
described the seven stages the idea went through before it eventually
entered the field of routine clinical practice:
1. Initial stage: “Won’t work; been tried before.”
2. After successful experiments in animals: “Won’t translate to man.”
3. After 1 successful clinical patient: “Very lucky; doubt if patient really needed
transplant.”
4. After 4 or 5 clinical successes: “Highly experimental, too risky, immoral,
unethical; I understand they have had a number of deaths they are not
reporting.”
5. After 10 to 15 patients: “May succeed occasionally in carefully selected cases
but very few patients really need an operation anyway.”
6. After a large series of successes: “So and so has been unable to duplicate
their results. I hear that a number of their patients are now dying late death.”
7. Final stage: “This is a very fine contribution. A straightforward solution to a
difficult problem. I predicted this. In fact, in 1939 I had the same idea. Of
course, we didn’t publish anything. We had no cyclosporin.”
The time frame of this evolution took more than 20 years, between 1960 and 1982.
The heroic days of ground-breaking cardiac surgery have long passed, and progress
ow relies on evidence-based medicine. To enter the field of routine clinical practice,
ew ideas (including techniques or technologies) need comparison with the established
old standards and demonstration of statistically superior measurable end points. Until
rospective, randomized, controlled trials possibly close discussions between the sup-
orters and doubters, who will turn into “early adopters” and “laggards” if the technique
ecomes the next gold standard, it is desirable and rational to debate ideas and comment
n data. Nonetheless, before reading the editorials about robotics, one should recall that
he report of data from a “large cohort” represents a level B of evidence, whereas expert
pinion corresponds to a level C.1
Besides evidence-based medicine, progress in 2007 is as dependent on a “vision”
s it was 40 years ago. The vision that supports the development of robotics in
ardiac surgery is simple: it is that the next challenge our profession needs to face
s to decrease its complications and costs.2 This correlates entirely with a decrea
n physiologic insult, that is, invasiveness of the surgical procedures. The technol-
gy-based reduction of invasiveness is a natural step in the evolution of a mature
urgical discipline. It has happened in gynecologic, digestive, vascular, and neuro-
urgical fields, as well as in urology, otorhinolaryngology, and so on. In every single
ase, the time frame between the initial “idea” stage and the maturity of the
rocedure has been lengthy. Many of us will recall the early days of these techniques
hen they were described as “purely cosmetic” by their opponents.
In the arena of cardiac surgery, the challenge of minimal invasiveness is com-
licated. Foremost, the consequence of failure is dramatic—rapidly irreversible or
ethal—as opposed to other disciplines. This fact hinders the willingness to radically
hange successful procedures. Second, dealing with fragile microstructures such as
oronary arteries or mitral chordae from a distance could not be achieved with the
xisting endoscopic cameras and instruments. The advent of robotic telemanipula-
ion, coupled, as discussed in this issue of the Journal,3 with the possibility of a s
ail-out mode, paved the way for closed-chest heart surgery. Although the point was
ot to reinvent the wheel and perform new types of operations, this resulted in a
vascular Surgery ● September 2007
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Luge paradigm shift in the operating room. The successful
doption of this paradigm shift has been reported as the
ltimate example of a team effort.4
This point is clearly explained in the editorial by Dami5
hich reports that the expectations were high. However, this
ditorial does endorse the great responsibility of declaring that
project of significant magnitude has a place in the obituary
olumn. The magnitude of the project to bring robots to the
ardiac operating room, I must admit, involves not only med-
cal, but also scientific, technologic, and even financial impli-
ations. The project is made possible by the converging work
f more than 200 engineers and numerous surgeons.
The surgeons who authored the article about robotics are all
rom an academic background, and robotics is indeed only a
mall fraction of their practice. They strongly believe that they
re the gatekeepers of their patient’s interests, and they will not
esitate to present negative results to their peers.
But the authors3 believe also that comments such as 
promise is unfulfilled,” “the technology has lived up to its
otential,” the patients were “put at risk for a purely cos-
etic benefit,” or the technology “has failed to demonstrate
ny clinical value, outside of its questionable use for mar-
eting,”5 are supported by significantly biased shortcuts 
umerous errors.
“The Emperor’s New Clothes” insists heavily on the
ifespan of the project. Even though the modern world is
ostly driven by quarterly results, so that 10 years appears
o be an obscene period of time for the adoption of new
echnology, it nonetheless has not been “almost a decade”
ince the first use of robotics. A couple of cases were
erformed with prototypes in 1998.6 The da Vinci systems
Intuitive Surgical, Inc, Mountain View, Calif) were intro-
uced in clinical use in 2001. This article reports the early
uropean experience between 2001 and 2005. Data collec-
ion and analysis and the publication process took place
hereafter. Therefore, the time frame under scrutiny is ac-
ually less than 5 years and not 10.
Opponents to robotics5 refer largely to experience wi
he late Zeus system (Computer Motion, Inc, Goleta, Calif),
hich did not initially have mobile articulations at the tip of
he instrument.7–9 The lack of this feature was clearly -
ompatible with reproducible performance of an anastomo-
is in the real world, although some astonishing successes
ere reported.7 References to the Zeus system7–9 are
amely quoted in this issue of the Journal5 to support th
dea that “robotics also have been uniformly shown to slow
he completion of gross motor skills,” whereas the article by
iodato and associates9 concludes: “Compared with perfo-
ance on a standard laparoscopic trainer, robotic assistance
llows for increasing speed and consistency while maintain-
ng precision over multiple repetitions.”
The editorial5 tends to demonstrate [as per two previ
tudies from coauthors of the cited article3] the following: c
The Journal of Thoracichat totally endoscopic coronary artery bypass (TECAB) on
he arrested heart is not an option owing to long crossclamp-
ng and cardiopulmonary bypass (CPB) times; that although
patency was very good,” the only “reasonable option” is
eating heart surgery, but then beating heart TECAB is “too
ifficult”; and, finally, that “no attempt was made to com-
are TECAB to the gold standard.”
This again looks like a questionable shortcut. Although
ong crossclamping and CPB times are obviously not desir-
ble, it is also quite clear, after a steady state was reached in
he caseload of off-pump coronary artery bypass, that CPB
s not a crime in low-risk patients. The articles that report
ery long crossclamp times refer to the very first cases that
ere performed worldwide. Who would have expected
hort bypass times at this point? In the current experience,
hich takes place after the learning period, the clamping
ime to perform anastomosis when the heart is arrested has
ecreased steeply to about 10 minutes.
If it was hypothesized 10 years ago, when the definition
tself of less invasive surgery was unclear, that most of the
nflammatory reaction came from CPB, then this has been
ontradicted. Some evidence has now been published to
how that a smaller incision was the catalyst to less inflam-
atory reaction. Also, as adressed by Damiano,5 arrested
eart TECAB may be easier to perform than beating heart
ECAB, thus leading to superior reproducibility. For all those
easons, the authors3 believe that arrested heart TECAB c
emain an option in the future of (multivessel?) surgical revas-
ularization that cannot be discarded at this time.
igure 1. 1 and 3 correspond to added value of TECAB and DES
ompared to classical CABG and PCI, respectively. 2 and 4 corre-
pond to tradeoffs for those added values, respectively. The mea-
urements of those added values and tradeoffs require PRCTs. Only
RCTs will tell if the decrease in restenosis justifies the increase in
ate failure/death in DES and if the decrease in complications jus-
ifies longer bypass times or lower patency rates in TECAB. At this
oint, this report3 can assess that efficacy is in the range of the
xpected values for CABG from STS on/off pump matched for indi-
ations (arbitrary zone of noninferiority is shaded).
and Cardiovascular Surgery ● Volume 134, Number 3 563
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LAs far as beating heart TECAB is concerned, high rates
f conversion were no surprise either in the early days of the
rocedure. The fact that conversion does not compromise
he outcome is seen as a bail-out, which is part of the overall
rocedural safety. The rate of conversion is clearly corre-
ated with the learning curve.3
It is not correct that “no attempt was made to compare
hese results to either open coronary bypass grafting, or
IDCAB procedures.” The results were compared with a
ociety of Thoracic Surgeons cohort that was matched for
ndications and techniques (single left internal thoracic ar-
ery to left anterior descending artery, on-pump, or off-
ump). This comparison is commented on throughout the
ext and in Table 4 of the report.3
The reality is, at present, no one, including the authors of
he study, can predict whether robotic technology is or is not
oing to play a major role in the future of cardiac surgery
nd what the time frame will be.
The success or failure of robotics will rely on many
ariables, some outside the surgical community: factors
uch as the willingness of a monopolistic industry to further
nvest in the refinement of the system, the development of
djuvant platforms to make the operations more operator
riendly, and the development of training programs, data-
ases, and networks.
It is a fact, though, that patients reported in our pilot
tudy have been operated on and the results reviewed by the
ood and Drug Administration. The report of this fact can
e valuable to the members of our community. It enables the
uthors to affirm that closed-chest coronary artery bypass
rafting is feasible. When compared with the gold standard,
he results demonstrate no statistical difference in mortality
r patency. The authors3 believe that this enables them 
ddress the issue of safety and efficacy of robotics. In the
arly days of a new technology, the concept of noninferi-
rity (Figure 1) might have been used and would have
n even better case to support the hypothesis.10
However, mostly, it is the added value that TECAB
enerates that will make it a success or not. This added
alue was not the end point of the article and, for the sake
f clarity, needs to be adressed in future reports.
64 The Journal of Thoracic and Cardiovascular Surgery ● Septen
In summary, what the candid observer would tend to call
ure cosmesis (Figure 2) actually means no blood–air
erface, leading to much less inflammatory reaction, no risk
f infection, and no aortic cannulation: in short, eviction of
he maneuvers that generate most of the morbidity in cor-
nary artery bypass grafting.
In the end, the patients and their cardiologists might be
illing to take advantage of this added value if it is repro-
uced routinely in numerous institutions throughout the
orld. It is a semantic error to call it marketing. Added
alue is one definition of progress.
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